RXRX RECURSION PHARMACEUTICALS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1601830 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY56.2%
TTM net income YoY33.5%
TTM EPS YoY53.3%
Revenue 3-yr CAGR12.9%
Net income 3-yr CAGR—
Margins
Gross margin29.2%
Operating margin-725.4%
Net margin-697.1%
FCF margin-458.0%
EBITDA margin-617.2%
Returns
ROE-48.7%
ROA-36.3%
ROIC (approx.)-101.8%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets25.9%
Debt / equity0.01x
Current ratio5.01x
Interest coverage-541.56x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $74.68M | $58.84M | $44.58M | $39.84M | $10.18M |
| Cost of revenue | $70.95M | $45.24M | $42.59M | $48.27M | $0 |
| Gross profit | $3.73M | $13.60M | $1.99M | -$8.43M | $10.18M |
| R&D expense | $475.27M | $314.42M | $241.23M | $155.70M | $135.27M |
| SG&A expense | $176.59M | $178.18M | $110.82M | $81.60M | $57.68M |
| Operating income | -$648.13M | -$479.00M | -$350.06M | -$245.73M | -$182.78M |
| Interest expense | $1.81M | $1.57M | $97,000 | $55,000 | $2.95M |
| Pretax income | -$644.89M | -$464.79M | -$332.13M | -$239.48M | -$186.48M |
| Income tax | -$136,000 | -$1.13M | -$4.06M | $0 | $0 |
| Net income | -$644.76M | -$463.66M | -$328.07M | -$239.48M | -$186.48M |
| EBITDA | -$564.43M | -$442.51M | -$325.66M | -$233.97M | -$174.37M |
| EPS (basic) | -1.44 | -1.69 | -1.58 | -1.36 | -1.49 |
| EPS (diluted) | -1.44 | -1.69 | -1.58 | -1.36 | -1.49 |
| Weighted avg. shares (diluted) | 447.45M | 274.21M | 207.85M | 175.54M | 125.35M |
| Balance sheet | |||||
| Cash & equivalents | $743.29M | $603.02M | $401.43M | $559.11M | $295.35M |
| Short-term investments | — | — | — | $0 | $231.45M |
| Receivables | — | — | — | $0 | $34,000 |
| Current assets | $812.85M | $714.27M | $438.14M | $569.81M | $534.72M |
| PP&E, net | $103.93M | $141.06M | $86.51M | $88.19M | $64.72M |
| Goodwill | $162.16M | $148.87M | $52.06M | $801,000 | $801,000 |
| Intangibles | $309.90M | $335.86M | $36.44M | $1.31M | $1.39M |
| Total assets | $1.47B | $1.45B | $653.70M | $701.29M | $610.35M |
| Current liabilities | $147.71M | $187.47M | $93.17M | $100.27M | $46.66M |
| Short-term debt | $9.09M | $8.43M | $41,000 | — | — |
| Long-term debt | $9.56M | $19.02M | $1.10M | — | $723,000 |
| Total debt | $18.66M | $27.45M | $1.14M | — | $723,000 |
| Total liabilities | $343.26M | $413.82M | $190.26M | $215.48M | $67.41M |
| Shareholders' equity | $1.13B | $1.03B | $463.44M | $485.81M | $542.94M |
| Net debt | -$724.64M | -$575.58M | -$400.28M | — | -$294.63M |
| Shares outstanding | 528.18M | 396.80M | 234.27M | 191.02M | 170.27M |
| Cash flow statement | |||||
| Operating cash flow | -$371.81M | -$359.17M | -$287.78M | -$83.52M | -$158.61M |
| Capital expenditure | $6.47M | $13.70M | $11.96M | $37.06M | $39.80M |
| Free cash flow | -$378.28M | -$372.87M | -$299.74M | -$120.58M | -$198.41M |
| Investing cash flow | -$16.87M | $260.06M | -$10.23M | $193.25M | -$271.74M |
| Financing cash flow | $521.53M | $304.12M | $140.13M | $154.34M | $458.54M |
| Depreciation & amortization | $83.70M | $36.49M | $24.40M | $11.76M | $8.40M |
| Stock-based compensation | $111.22M | $81.69M | $53.50M | $27.91M | $14.84M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.